326 related articles for article (PubMed ID: 31480004)
1. Combined MEK inhibition and tumor-associated macrophages depletion suppresses tumor growth in a triple-negative breast cancer mouse model.
Zhang Q; Le K; Xu M; Zhou J; Xiao Y; Yang W; Jiang Y; Xi Z; Huang T
Int Immunopharmacol; 2019 Nov; 76():105864. PubMed ID: 31480004
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
3. Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
Frankenberger C; Rabe D; Bainer R; Sankarasharma D; Chada K; Krausz T; Gilad Y; Becker L; Rosner MR
Cancer Res; 2015 Oct; 75(19):4063-73. PubMed ID: 26238785
[TBL] [Abstract][Full Text] [Related]
4. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE.
Qiao J; Chen Y; Mi Y; Jin H; Wang L; Huang T; Li H; Song Y; Cao J; Wu B; Wang Q; Zou Z
Biochem Pharmacol; 2020 Oct; 180():114126. PubMed ID: 32603665
[TBL] [Abstract][Full Text] [Related]
5. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
[TBL] [Abstract][Full Text] [Related]
7. Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
Ono H; Horinaka M; Sukeno M; Morita M; Yasuda S; Nishimoto E; Konishi E; Sakai T
Cancer Sci; 2021 Oct; 112(10):4166-4175. PubMed ID: 34288272
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 blockade TAM-dependently potentiates mild photothermal therapy against triple-negative breast cancer.
Wang C; Xu YH; Xu HZ; Li K; Zhang Q; Shi L; Zhao L; Chen X
J Nanobiotechnology; 2023 Dec; 21(1):476. PubMed ID: 38082443
[TBL] [Abstract][Full Text] [Related]
10. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
11. Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer.
Deng Y; Hu JC; He SH; Lou B; Ding TB; Yang JT; Mo MG; Ye DY; Zhou L; Jiang XC; Yu K; Dong JB
Acta Pharmacol Sin; 2021 Jan; 42(1):149-159. PubMed ID: 32451413
[TBL] [Abstract][Full Text] [Related]
12. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer cells promote CD169
Jing W; Guo X; Wang G; Bi Y; Han L; Zhu Q; Qiu C; Tanaka M; Zhao Y
Int Immunopharmacol; 2020 Jan; 78():106012. PubMed ID: 31865052
[TBL] [Abstract][Full Text] [Related]
14. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
15. MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
Bartholomeusz C; Xie X; Pitner MK; Kondo K; Dadbin A; Lee J; Saso H; Smith PD; Dalby KN; Ueno NT
Mol Cancer Ther; 2015 Dec; 14(12):2773-81. PubMed ID: 26384399
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
17. Liposome-encapsulated zoledronate increases inflammatory macrophage population in TNBC tumours.
Petruk N; Sousa S; Croset M; Polari L; Zlatev H; Selander K; Mönkkönen J; Clézardin P; Määttä J
Eur J Pharm Sci; 2023 Nov; 190():106571. PubMed ID: 37652236
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of tumor-associated macrophages in pancreatic neuroendocrine tumors.
Krug S; Abbassi R; Griesmann H; Sipos B; Wiese D; Rexin P; Blank A; Perren A; Haybaeck J; Hüttelmaier S; Rinke A; Gress TM; Michl P
Int J Cancer; 2018 Oct; 143(7):1806-1816. PubMed ID: 29696624
[TBL] [Abstract][Full Text] [Related]
19. TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer.
Lee C; Kim S; Jeong C; Cho I; Jo J; Han IH; Bae H
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216272
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.
Niu M; Valdes S; Naguib YW; Hursting SD; Cui Z
Mol Pharm; 2016 Jun; 13(6):1833-42. PubMed ID: 27074028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
